poster
Frontage Genomics Services has validated a custom-designed 293 cancer-related genes panel. A key application is the determination of BRCA1/2 mutation status to qualify for a personalized treatment called Gemogenovatucel-T, a cellular immunotherapy that improves recurrence-free and overall survival only in ovarian cancer patients with no mutations in BRCA1/2 genes. This panel enables rapid analysis of genomic DNA from blood using hybridization-based library preparation, sequencing on the Illumina NextSeq2000 platform and accurate screening with full coverage of BRCA1/2 exons and adjacent introns. This panel is also capable of detecting somatic variants with high sensitivity of up to 3% allele fraction, supporting biomarker discovery, cancer biology research and drug development.
Register to gain access to gated resources.
"*" indicates required fields
Frontage Laboratories websites use cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details about cookies, and their use, please see our privacy policy.
Websites store cookies to enhance functionality and personalise your experience. You can manage your preferences, but blocking some cookies may impact site performance and services.
Essential cookies enable basic functions and are necessary for the proper function of the website.